Company news

Quanterix Corporation news in 2026

Quanterix Corporation's news releases, calls and decks from 2026, newest first.

View company

Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026

October 28, 2026

Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

October 7, 2026

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

September 25, 2026

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

September 14, 2026

Quanterix Names Jim Gute Chief Commercial Officer

August 10, 2026

Quanterix Releases Financial Results for the Second Quarter of 2026

August 10, 2026

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

August 6, 2026

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026

August 4, 2026

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 16, 2026

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

July 14, 2026

Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer

June 9, 2026

Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

June 3, 2026

Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 3, 2026

Quanterix Announces Planned Transition of Chief Financial Officer

May 12, 2026

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows

May 6, 2026

Quanterix to Report First Quarter 2026 Financial Results on May 6, 2026

April 27, 2026

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

April 24, 2026

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

April 17, 2026

Quanterix Debuts Content Innovation Engine at AACR 2026

April 15, 2026

Quanterix Corporation Announces Date of 2026 Annual Meeting

March 26, 2026

Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025

March 2, 2026

Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

March 2, 2026

Quanterix to Participate in Upcoming Investor Conferences

February 26, 2026

Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

February 20, 2026

Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection

February 3, 2026

Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling

January 21, 2026

Quanterix Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

January 19, 2026

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

January 8, 2026

Calls in 2026

Decks in 2026